Advaxis To Seek New Life In Merger With Ayala

The new company will focus mainly on Ayala’s lead candidate for desmoid tumors, but minority owner Advaxis will take over management.

Mismatch
Advaxis and Ayala plan a merger of dissimilar cancer companies • Source: Shutterstock

Troubled Advaxis, Inc. may be getting a second lease on life by merging with cash-poor Ayala Pharmaceuticals, Inc., which has a late-stage candidate for desmoid tumors, a condition with no approved drug therapy, although it appears to trail competitor SpringWorks Therapeutics Inc. on both efficacy data and timeline for reaching the market in that indication.

The two companies announced their planned merger on 19 October, though it still requires approval by Ayala shareholders. An all-stock...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.